Panagiotis Mavros

Statistics

Publications

Citations

3.5K

H-Index

Active since

1995

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Janssen Scientific Affairs (United States)

Medical University of Vienna

Janssen (United States)

MSD (Spain)

Panagiotis Mavros is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and clinical pharmacology.

ORCID

Publications per year

1995–2023

Publications

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

Hans‐Georg Eichler, Sheldon X. Kong, William C. Gerth et al. · Value in Health · 2004 · 803 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +15

Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment

Brigitte Bloechl‐Daum, Robert Deuson, Panagiotis Mavros et al. · Journal of Clinical Oncology · 2006 · 505 citations

Medicine, Oncology, Pharmacology +17

Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics

Steven M. Grunberg, Robert Deuson, Panagiotis Mavros et al. · Cancer · 2004 · 470 citations · Full text

Nursing, Oncology, Oncology Nursing +15

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real‐Life Effectiveness and Care Patterns of Diabetes Management (RECAP‐DM) Study

Fernando Álvarez Guisasola, Girishanthy Krishnarajah, R. Lyu et al. · Diabetes Obesity and Metabolism · 2008 · 192 citations

Medicine, Internal Medicine, Clinical Pharmacology +16

Do Doctoral Students' Financial Support Patterns Affect Their Times-To-Degree and Completion Probabilities?

Ronald G. Ehrenberg, Panagiotis Mavros · The Journal of Human Resources · 1995 · 158 citations · Full text

Education, Higher Education, Enrollment Management +13

1–5 of 39